Insight Molecular Diagnostics Inc (IMDX) — Titan Protect Analysis

IMDX

Insight Molecular Diagnostics Inc

Healthcare · ·

$5.24

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$188M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.46

Based on estimated future earnings — lower means cheaper

Rev Growth

-98.5%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$9.00

+72% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Insight Molecular Diagnostics Inc

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa

https://www.imdxinc.com

Country: United States Employees: 55 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.946

Good returns relative to risk taken

Kelly Fraction

0.0432

Modest edge detected — smaller position warranted

Calmar Ratio

0.824

Acceptable balance between returns and drawdown risk

Annual Return

57.6%

Historical annualised return based on price data

Max Drawdown

-69.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$8.51

38% below the year high

52W Low

$2.33

125% above the year low

Avg Volume

347,163

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.51

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

51.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-32,284.4%

Profit from core operations before interest and tax

Free Cash Flow

$-15,769,625

Negative — the business is spending more than it generates

Revenue (TTM)

$2M

Total revenue over the last 12 months

Net Income

$-47,841,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$9.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go